Deferasirox.
| Characteristics | |
| Route of administration | PO |
| Half-life | 8 to 16 hours |
| Primary route of iron excretion | Stool |
| Dose range | 20–30 mg/kg/d |
| Guidelines for Monitoring Therapy | |
| Serum creatinine level monthly | |
| ALT level monthly | |
| Serum ferritin level monthly | |
| Assessment of liver iron annually | |
| Assessment of cardiac iron annually after 10 years of age | |
| Advantages | |
| Orally active | |
| Once daily administration | |
| Demonstrated equivalency to deferoxamine at higher doses | |
| Trials in several hematologic disorders | |
| Disadvantages | |
| Limited long-term data | |
| Need to monitor renal function | |
| May not achieve negative iron balance in all patients at highest recommended dose | |
| Characteristics | |
| Route of administration | PO |
| Half-life | 8 to 16 hours |
| Primary route of iron excretion | Stool |
| Dose range | 20–30 mg/kg/d |
| Guidelines for Monitoring Therapy | |
| Serum creatinine level monthly | |
| ALT level monthly | |
| Serum ferritin level monthly | |
| Assessment of liver iron annually | |
| Assessment of cardiac iron annually after 10 years of age | |
| Advantages | |
| Orally active | |
| Once daily administration | |
| Demonstrated equivalency to deferoxamine at higher doses | |
| Trials in several hematologic disorders | |
| Disadvantages | |
| Limited long-term data | |
| Need to monitor renal function | |
| May not achieve negative iron balance in all patients at highest recommended dose | |